Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Newly Established VC Fund Invests in Innovative Digital Health and Medtech/Diagnostics Technologies with Software Components

12 Jul

A new venture fund started investing in pre-seed, seed and Series A rounds. The firm’s main investment areas are in companies that advance and improve human health through novel models of care delivery and in companies that are at the cutting-edge of frontier technology, such as neurotech, brain/machine interfaces, genomics and AI. The firm will consider digital health companies as well as diagnostics and medical device companies, as long as they have a software component. The firm will only invest in companies with disruptive technology, not incremental innovations. The firm will invest between $.1-1.5M in the initial investment, with the possibility of participating in following rounds. The firm is willing to lead or co-invest, has made 7 investments to date and is looking to invest in 4-6 companies a year.

The firm will consider digital health companies that are focused on improving patient care. Ideally, companies will already have a pilot with some outcomes-based data indicating traction. The firm is also interested in medical device companies, but will only invest if there is a significant software and/or radical innovation component. The firm will also consider diagnostics, such as genomics-based technologies, but not in vitro diagnostics. The firm will not invest in traditional therapeutics (i.e. small molecule or biologics) companies but will consider software-as-medicine and bioelectronic medicine.

Due to the firm’s preference for cutting-edge technology, the firm prefers that there be at least one technical expert in the company leadership. If acting as a lead investor, the firm will take a board or board observer seat. The firm prefers to be an active investor, providing multi-faceted support to portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

5 Jul

A Seoul-based venture capital firm founded in 2015 and affiliated with a leading pharmaceutical company in South Korea closed their first fund in 2016 and has recently raised a second fund of approximately $60M USD. The firm has made 8 investments to date, in 3 Korean and 5 USA-based companies. The firm continues to seek global opportunities. The firm generally participates in financings of Series B and beyond, participating in Series A rounds on a case-by-case basis. However, the firm has started to look for earlier stage opportunities and is most interested in spin-out assets and forming new companies in South Korea. Within this angle, the firm is highly interested in companies who are interested in entering the Korean market and looking to leverage on the capital and clinical infrastructure in South Korea.

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.

With regards to companies raising a Series A round, the firm prefers working with experienced management teams with high-profile scientific founders being involved. The firm incorporates a different strategy depending on the company’s headquarters. For companies based in South Korea, the firm serves as a hands-on, active investor and seeks board representation. In the USA, the firm prefers to be a more passive investor and generally seeks to co-invest with established venture capital firms that have a footprint in the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

5 Jul

A boutique venture capital firm founded in Hong Kong currently manages a $100M USD fund and a $200M RMB fund. The fund is industry agnostic within China while it focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: